ARCTURUS THERAPEUTICS HOLDIN

ARCTNASDAQ

🏆 #2895 by market capEarnings Nov 9US Equity

$967.27▲ $60.74 (+6.28%)

Simulated price

1h—

24h▲ 6.3%

7d—

14d—

30d—

1y—

🏦Market Cap

$214M

Small Cap

📈Revenue Growth (YoY)

-76.0%

Declining

📊Gross Margin

—

💵FCF Margin

704.6%

Strong

⚖️P/S Ratio

6.8x

Fair

Otter Score

Fair

No chart data available for ARCT.

Trading Snapshot

Day Range: $960.86 – $985.12
52-Week Range: $5.50 – $24.17
Volume: $2.69B
Avg Volume: $2.55B
Shares Outstanding: 28.4M
Next Earnings: Aug 31, 2026

Fundamentals Snapshot

Annual Revenue: $67M
Last Q Revenue: $3M
P/E Ratio: —
P/S Ratio: 6.8x
EPS (TTM): $-3.31
Dividend Yield: —

Why Investors Own ARCT

✓High-growth profile — revenue up +53.9% YoY with expanding US Equity exposure.
✓Healthy economics — 57% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$67M▲ +57.2% YoY

Gross Margin (TTM)

57.2%▲ +0.9% YoY

Operating Income (TTM)

$20M▲ +57.2% YoY

Free Cash Flow (TTM)

$10M▲ +57.2% YoY

About ARCTURUS THERAPEUTICS HOLDIN

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.

🦦